Identifying Blood-Based Markers for Optimized Bipolar Androgen Therapy in mCRPC

[madman]

To view this content we will need your consent to set third party cookies.
For more detailed information, see our cookies page.

Accept third party cookies

Samuel Denmeade, MD, of Johns Hopkins University School of Medicine, highlights his research on blood-based markers of differential efficacy of bipolar androgen therapy and enzalutamide in the randomized TRANSFORMER trial.

This research was presented as a late-breaking abstract at the 2024 American Society of Clinical Oncology Annual Meeting.

 

[madman]

 

[madman]

 

[madman]

 

[madman]

 

[madman]

 

[madman]

Bipolar androgen therapy in prostate cancer: Current evidence and next steps

"We've been doing a lot of work at Johns Hopkins using high-dose testosterone therapies to treat patients with metastatic prostate cancer," says Mark C. Markowski, MD, PhD. https://www.urologytimes.com/view/bipolar-androgen-therapy-in-prostate-cancer-current-evidence-and-next-steps In this...

www.excelmale.com

 

[madman]

Dr. Samuel Denmeade on Bipolar Androgen Therapy for Prostate Cancer

* This approach involves administering high doses of testosterone, which has shown significant improvement in 30% of patients, enhancing strength, energy, and sexual function * their research uses blood-based DNA markers to predict which patients will respond best, aiming to personalize...

www.excelmale.com